IDEXX Laboratories (IDXX) Stock Price
IDEXX Laboratories Price
Over the last 19 years IDEXX Laboratories grew revenue by 9.7% annually, reaching 4.30 B USD. Earnings per share have grown at 16.2% per year over the last 19 years. For IDEXX Laboratories, the net margin of 24.6% is up versus 23.2% a few years ago. The consensus 12-month price target for IDEXX Laboratories is 665.00 USD, about 28.4% above where the stock trades today. Of 22 analysts, 14 rate the stock a buy — an overall Buy consensus.
IDEXX Laboratories stock price
IDEXX Laboratories business model & stock analysis
Frequently asked questions about IDEXX Laboratories
IDEXX Laboratories Inc is a global leader in veterinary diagnostics and software solutions. Their business model revolves around providing innovative products and services to veterinary practices, livestock producers, and pharmaceutical companies. IDEXX offers a wide range of diagnostic tests, instruments, and consumables that aid in the detection and prevention of diseases in animals. Their software solutions enable veterinary practices to streamline their operations, manage patient data, and enhance overall patient care. With a strong focus on research and development, IDEXX continuously strives to introduce advanced technologies and improve the quality of veterinary care worldwide.
IDEXX Laboratories Inc is primarily active in the animal health industry.
The main competitors of IDEXX Laboratories Inc in the market are Zoetis Inc, Heska Corporation, and Abaxis, Inc.
IDEXX Laboratories Inc. is a leading global company in veterinary diagnostics and software solutions. Founded in 1983, IDEXX has built a strong reputation for offering innovative products and services to support the animal healthcare industry. The company's mission is to improve the health and well-being of pets, livestock, and wildlife. IDEXX provides a wide range of diagnostic tests, instruments, and digital imaging systems that help veterinarians accurately diagnose diseases and ensure the best possible care for animals. With its headquarters in Maine, USA, IDEXX has an extensive network of customers worldwide. As a pioneer in animal diagnostics, IDEXX continues to drive advancements in veterinary medicine and enhance animal healthcare globally.
IDEXX Laboratories Inc, a renowned leader in veterinary diagnostics and software, has achieved numerous significant milestones over the years. The company pioneered the first veterinary reference laboratory, revolutionizing the field of animal health diagnostics. IDEXX also developed innovative technologies such as the SNAP test, providing immediate results for veterinarians. Furthermore, the company introduced groundbreaking products like the IDEXX ProCyte Dx Hematology Analyzer, enhancing the accuracy and efficiency of pet healthcare. With a commitment to continuous innovation, IDEXX Laboratories Inc has consistently redefined the standards in veterinary medicine, offering exceptional diagnostic solutions for veterinarians globally.
IDEXX Laboratories Inc is primarily present in various countries and regions worldwide. As a leading veterinary diagnostics and software provider, IDEXX operates in over 175 countries. Its operations span across North America, including the United States and Canada, as well as Europe, Asia-Pacific, Latin America, and the Middle East. With a strong global presence, IDEXX consistently delivers innovative solutions and services to veterinary practices, animal healthcare professionals, and laboratories around the globe.
IDEXX Laboratories Inc represents strong values and a clear corporate philosophy. The company's values are centered around innovation, integrity, and collaboration. IDEXX is committed to continuously developing innovative diagnostic solutions to improve the health and well-being of animals worldwide. They uphold the highest standards of integrity in their business practices, ensuring transparency and trust with their customers and partners. Additionally, IDEXX promotes a culture of collaboration, fostering a diverse and inclusive environment that encourages teamwork and supports the growth and success of its employees. Through these values and corporate philosophy, IDEXX Laboratories Inc exemplifies its dedication to advancing animal healthcare globally.
Analysts currently set an average price target of 665.00 USD for the IDEXX Laboratories stock (median: 665.00 USD), implying +28.4 % versus the latest price. The consensus is based on 22 analyst ratings.
22 analysts currently rate the IDEXX Laboratories stock: 14 recommend buying, 8 holding and 0 selling. For 2026, analysts expect IDEXX Laboratories to generate revenue of 4.72 B USD and earnings per share of 14.82 USD.
Converted at the current exchange rate, the IDEXX Laboratories share trades at 462.32 EUR (518.07 USD).
The IDEXX Laboratories share (IDXX) is listed on 9 stock exchanges, including: NASDAQ (IDXX), London (0J8P.L), SIX (Zürich) (IX1.SW), XETRA (IX1.DE), Frankfurt (IX1.F), München (IX1.MU), Düsseldorf (IX1.DU), Wien (IDXX.VI).
IDEXX Laboratories Inc is a leading company in the field of animal health diagnostics and biotechnology. The company's business model is to offer innovative solutions to veterinarians, pet owners, and animal caretakers to improve the health and well-being of animals. IDEXX is divided into three main divisions: diagnostics and software, water testing, and animal genetics. Each division offers specialized products and services to meet the individual needs and requirements of customers. The diagnostics and software division of IDEXX offers a wide range of tests and instruments for the diagnosis of diseases in animals. The products range from simple blood tests to complex pathological examinations. IDEXX Labs specializes in tests for dogs, cats, and horses, offering a wide range of diagnostic options for these animals. The company also works closely with veterinarians and veterinary clinics to provide a wide range of diagnostic and laboratory services. In the water testing division, the company develops solutions for the detection of contaminants in drinking water and bottled water. This area of the business is focused on companies and government agencies that monitor the condition of water and want to ensure that it is safe for consumption. The animal genetics division of IDEXX offers breeding programs and tests for animals. The foundation of this division's work is DNA sequencing, which allows for the identification of genetic factors that can impact the health and behavior of animals. The animal genetics department works with veterinarians and pet owners to provide customer-oriented services that contribute to the improvement of animal health and breed. IDEXX is committed to providing its customers with innovative and advanced solutions. The company continuously invests in research and development to bring new products to the market and improve its existing offerings. IDEXX's business model is based on creating value by helping veterinarians and animal caretakers improve the health, well-being, and quality of life of animals. IDEXX also aims to integrate its products and services into the online market. To achieve this, the company develops various software solutions to ensure better portability and convenient connections to its services for customers. IDEXX is already involved in telemedicine, offering pet owners the opportunity to speak with veterinarians online and receive diagnoses. Overall, IDEXX's business model is focused on providing a comprehensive platform for animal health and biotechnology. Through its divisions in diagnostics, water testing, and animal genetics, the company has developed a wide range of products and solutions aimed at improving the health and well-being of animals and providing customers with high value.
The expected revenue of IDEXX Laboratories is 4.72 B USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of IDEXX Laboratories is 1.20 B USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of IDEXX Laboratories is currently 34.96. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the IDEXX Laboratories stock.
The price-to-sales ratio (P/S) of IDEXX Laboratories is currently 8.85. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the IDEXX Laboratories stock.
The Eulerpool Quality Score for IDEXX Laboratories is 8/10.
The ISIN of IDEXX Laboratories is US45168D1046. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of IDEXX Laboratories is 888210. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of IDEXX Laboratories is IDXX. The ticker symbol is used to trade IDEXX Laboratories shares on the stock exchange.
IDEXX Laboratories stock
IDEXX Laboratories Peer Group
IDEXX Laboratories Ticker
IDEXX Laboratories FIGI
All fundamentals and in-depth analysis of IDEXX Laboratories
Our stock analysis for IDEXX Laboratories stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of IDEXX Laboratories. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.